Although there was no significant difference in TP53 mutations between male and female lung cancer patients in the early stage, estrogen-induced DNMT expression to inhibit p53 expression, which might be one of the critical reasons for the induction of genomic instability, subsequently increasing TP53 mutation rates in the late stage of lung cancer in female patients. The gene discussed is TP53; the disease is lung carcinoma.